2010
DOI: 10.1038/onc.2010.229
|View full text |Cite
|
Sign up to set email alerts
|

Intermediate filament dynamics and breast cancer: Aberrant promoter methylation of the Synemin gene is associated with early tumor relapse

Abstract: Synemin (SYNM) is a type IV intermediate filament that has recently been shown to interact with the LIM domain protein zyxin, thereby possibly modulating cell adhesion and cell motility. Owing to this multiplicity of potential functions relevant to cancer development, we initiated a study to decipher SYNM expression and regulation in benign human breast tissue and breast cancer. Dot blot array analysis showed significant SYNM mRNA downregulation in 86% (n ¼ 100, Po0.001) of breast cancers compared with their n… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
42
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 46 publications
(42 citation statements)
references
References 42 publications
(55 reference statements)
0
42
0
Order By: Relevance
“…The differentially expressed proteins were more comprehensive and subtype-specific in the former data set, because of its larger the sample size and higher sequence coverage. Particularly, for the triple-negative subtype, which has been characterized by the high abundances of basal-like cytokeratins (56), SMOC1, S100B, GSTA1, SFRP1, S100A1, PTX3, SOX10, ANGPT2, COCH, as well as many other known markers such as SYNM1 (57), MFI2 (58), NDRG2 (59), CRYAB (60), and PLA2G4A (61) were found on top of the list of differential regulated proteins in the CPTAC data (supplemental Table S3). Markers are located on the scatter plot based on the fold changes relative to the three subtypes (axes) in log-scale.…”
Section: Resultsmentioning
confidence: 99%
“…The differentially expressed proteins were more comprehensive and subtype-specific in the former data set, because of its larger the sample size and higher sequence coverage. Particularly, for the triple-negative subtype, which has been characterized by the high abundances of basal-like cytokeratins (56), SMOC1, S100B, GSTA1, SFRP1, S100A1, PTX3, SOX10, ANGPT2, COCH, as well as many other known markers such as SYNM1 (57), MFI2 (58), NDRG2 (59), CRYAB (60), and PLA2G4A (61) were found on top of the list of differential regulated proteins in the CPTAC data (supplemental Table S3). Markers are located on the scatter plot based on the fold changes relative to the three subtypes (axes) in log-scale.…”
Section: Resultsmentioning
confidence: 99%
“…There are several biological functions that can be used to functionally categorize these biomarker genes. First, there is a set of genes associated with the cytoskeleton, extracellular matrix, angiogenesis, and hypoxia that includes SYNM (32), COL15A1, COL3A1, PTN (33), IFT57 (34), and MXI1 (35). Next, there is a set of cell cycle-related genes that includes CDC37L1, BTG2 (24), and SACM1L.…”
Section: Discussionmentioning
confidence: 99%
“…Pathologic conditions can induce synemin expression in diverse cell types, including reactive astrocytes, liver fibrotic cells (55,82,84), and glioblastomas (45,70). Synemin expression is also altered in myoepithelial cells of breast carcinomas due to changes in the methylation of the synemin gene (61). It is abundant in glioblastoma tumors (45) and in reactive astrocytes after neurotrauma and in Alexander disease (69).…”
Section: C455mentioning
confidence: 99%